Impact of abciximab and coronary stenting on outcomes and costs of percutaneous coronary interventions in a community hospital.
OBJECTIVE
To assess costs and outcomes of coronary stenting and balloon angioplasty with and without adjunctive treatment with abciximab for 3758 consecutive elective percutaneous coronary interventions at a single community center over the 2.5-year period between 1 January 1995 and 30 June 1997.


RESULTS
Abciximab was more common among patients who had recently suffered myocardial infarction, patients with unstable angina, and patients with more complex coronary lesions. Use of abciximab in conjunction with balloon angioplasty or stenting and stenting alone was associated with significant reductions in incidence of major adverse cardiovascular events in hospital. Multivariate analysis indicated that use of abciximab and stenting were associated with significant independent effects on risk of an event. Hospital costs were increased for patients administered abciximab, treated with stenting, or both. Total costs and costs inclusive of those incurred in catheterization laboratory and pharmacy increased significantly with increasing complexity of lesions. Multivariate regression analysis (baseline cost US$5621) identified death (US$16098), emergency revascularization (US$13678), usage of multiple stents (US$1423 for each stent), and use of abciximab (US$1269) as independent predictors of a greater cost. One-year follow-up revealed significant differences among treatment strategies in terms of risk of need for subsequent revascularization procedures. Lack of stenting but not use of abciximab was identified as a significant predictor of need for repeat revascularization procedures.


CONCLUSIONS
Our findings are in general agreement with cost analyses of use of abciximab for populations in clinical trials and suggest that improvements of early clinical outcome with abciximab treatment and stenting justify the incremental cost of treatment in a community hospital setting.
Prairie Education and Research Cooperative, Springfield, Illinois 62794-9420, USA. clucore@fgi.net
C L
CL
Lucore
R V
RV
Trask
G J
GJ
Mishkel
K J
KJ
Rocha-Singh
M E
ME
Shelton
F L
FL
Mikell
R W
RW
Ligon
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006764:Hospitals, Community / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012044:Regression Analysis; D015607:Stents / Q000191:economics; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab